Marksman Partners, L.P. v. Chantal Pharmaceutical Corp.

46 F. Supp. 2d 1042, 1999 U.S. Dist. LEXIS 11776, 1999 WL 235630
CourtDistrict Court, C.D. California
DecidedFebruary 24, 1999
DocketCV-96-0872 WJR (RNBX)
StatusPublished
Cited by2 cases

This text of 46 F. Supp. 2d 1042 (Marksman Partners, L.P. v. Chantal Pharmaceutical Corp.) is published on Counsel Stack Legal Research, covering District Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Marksman Partners, L.P. v. Chantal Pharmaceutical Corp., 46 F. Supp. 2d 1042, 1999 U.S. Dist. LEXIS 11776, 1999 WL 235630 (C.D. Cal. 1999).

Opinion

*1044 ORDER

1) DENYING CHANTAL PHARMACEUTICAL CORP. AND CHANTAL BURNISON’S MOTION FOR SUMMARY JUDGMENT, 2) DENYING STANSON MARKETING, INC. AND FRED REINSTEIN’S MOTION FOR SUMMARY. JUDGMENT, and 3) GRANTING COOPERS & LYBRAND L.L.P.’S MOTION FOR SUMMARY JUDGMENT

REA, District Judge.

On February 22, 1999, the Court heard oral argument regarding three separate motions for summary judgment brought by (1) Chantal Pharmaceutical Corporation (“Chantal”) and Chantal Burnison (“Burni-son”), (2) Stanson Marketing, Inc. (“Stan-son”) and Fred Reinstein (“Reinstein”), and (3) Coopers & Lybrand L.L.P. (“C & L”). After oral argument, the Court took each of the motions under submission for further consideration.

The Court now rules in accordance with its tentative ruling that was issued to the parties on February 22, 1999.. Thus, the Court hereby denies Chantal and Burni-son’s, and Stanson and Reinstein’s Motions for Summary Judgment as there are genuine issues of material fact relating to the claims against these parties. In addition, the Court hereby grants C & L’s Motion for Summary Judgment as there are no genuine issues of material fact relating to the claim against C & L.

I. Chantal’s Motion for Summary Judgment

Defendants Chantal and Burnison argue that Plaintiffs’ claim for securities *1045 fraud under Securities Exchange Act § 10(b) and Rule 10b-5 must fail. Defendants claim that Plaintiffs have no evidence of a fraudulent “ship and return” scheme between Chantal and Stanson leading to any illegal “insider trading” by Burnison that can form the basis for the securities fraud claim. Defendants also argue that Plaintiffs have not established that Chantal’s 1995 financial statements were fraudulent and misleading due to Stanson’s right to return goods under the distribution agreement. Specifically, Defendants maintain that Plaintiffs have no evidence that any goods were “returned” for any amount of credit that is material..

It is undisputed that 62% of Chantal’s reported 1995 sales were to Stanson. While Defendants claim that all product returns may have accounted for less than 1% of sales in 1995, Plaintiffs counter that the 1% figure applies only to returns from purchases made through Chantal’s 1-800 number. Plaintiffs assert that the returns from Stanson constituted over 60% of the total returns in 1995.

Plaintiffs allege that as a result of millions of dollars of product being returned by Stanson after payment was received, Chantal materially overstated net income by approximately $2.3 million, $0.7 million, and $7.4 million for the fiscal year ending 6/30/95, the third quarter ending 3/31/95, and the first quarter ending 9/30/95, respectively. These overstatements, in turn, caused earnings per share to be overstated by $0.17, $0.05, and $0.41 over the same periods. Thus, .this “ship-and-return” scheme artificially boosted Chantal’s stock price to an all time high immediately prior to Burnison’s 20% share sale of stocks.

Therefore, whether Stanson returned goods for credit, and whether these returns caused Chantal’s 1995 financial report to be fraudulent are genuine issues of material fact. Accordingly, summary judgment in favor of Defendants Chantal and Burnison is not appropriate.

II. Stanson and Reinstein’s Motion for Summary Judgment

A. Plaintiffs Have Sufficiently Established the Misleading Statements Made by the Stanson Defendants

The evidence .presented to this Court raises genuine questions of material fact as to the following issues: (i) how and when Reinstein told and directly participated in telling analysts and investors that Chantal products were enjoying wide and growing sales and distribution leading to impressive revenues, while he was preparing to sell 50,000 shares of Stanson’s Chantal stock; (ii) how Reinstein’s statements were made to analyst Gibson who was known to be following Chantal; (in) whether Gibson actually issued reports based on Reinstein’s statements and/or assurances of accuracy of information; (iv) whether Reinstein was present to give credibility as Chantal’s distributor when similar statements were made to a gathering of investors and analysts; and (v) whether Rein-stein knew his statements or assurances were false, given that most, if not all, of the Chantal product sold to Stanson was simply being held in warehouses, unsold.

B. The Evidence Also Establishes a Triable Issue on Stanson’s and Reinstein’s Scienter

Scienter is established by “ ‘proving either actual knowledge or recklessness.’ ” Provenz v. Miller, 102 F.3d 1478, 1490 (9th Cir.1996) (citation omitted). “Scienter can be established by direct or circumstantial evidence.” Id.

Here, the testimony of Carter, Burnison, and Reinstein all serve to raise genuine issues of material fact that Reinstein may have known that his statements to Gibson about the number of stores that would carry or were carrying Ethocyn and the 1996 and 1997 revenues Chantal would earn were false when made.

Reinstein apparently must, have known that millions of dollars of Chantal product which Stanson “bought” from Chantal *1046 were, simply being stored, not sold, because he signed the checks to pay the warehouse storage bills over a several month period.

In addition, Stanson’s receipt of Chantal stock, which was sold to pay for Chantal product, further raises genuine issues of fact regarding scienter in this alleged scheme. The sale of stock was made within weeks of Réinstein’s participation in the August presentation to analysts and investors which resulted in Gibson’s favorable report.

For the foregoing reasons, the Court denies Defendant Stanson and Reinstein’s Motion for Summary Judgment.

III. Coopers & Lybrand’s Motion for Summary Judgment

Defendant C & L argues that the undisputed facts in this case establish as a matter of law that C & L did not act with the requisite degree of scienter essential to maintain a fraud claim against an accounting firm under Section 10(b) of the Securities Exchange. Act of 1934 and Rule 10b-5. Plaintiffs, on the other hand, argue that C & L acted recklessly with respect to its audit of Chantal such that Plaintiffs can establish scienter. Moreover, Plaintiffs argue that Defendant G & L’s audit was so deficient that it amounted to no audit at all.

In order to establish liability under section 10(b), plaintiffs must show that the defendants acted with “a mental state embracing intent to deceive, manipulate, or defraud.” In re Software Toolworks, Inc., 50 F.3d 615, 626 (9th Cir.1994). With respect to auditors, the Ninth Circuit has found that “the mere publication of inaccurate accounting figures, or a failure to follow GAAP [Generally Accepted Accounting Principles], without more, does not establish scienter.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
46 F. Supp. 2d 1042, 1999 U.S. Dist. LEXIS 11776, 1999 WL 235630, Counsel Stack Legal Research, https://law.counselstack.com/opinion/marksman-partners-lp-v-chantal-pharmaceutical-corp-cacd-1999.